Back to top
more

Phreesia (PHR)

(Delayed Data from NYSE)

$20.61 USD

20.61
502,316

+0.15 (0.73%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $20.58 -0.03 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Stock Market News for Mar 18, 2024

by Zacks Equity Research

Wall Street closed lwer on Friday with the Fed facing an inflation dilemma ahead of the policy meeting.

Phreesia (PHR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Phreesia (PHR) give a sense of how its business performed in the quarter ended January 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 3.45% and 2.01%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?

Will Phreesia (PHR) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Phreesia (PHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 27.27% and 4.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

10x Genomics (TXG) delivered earnings and revenue surprises of -13.89% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Brian Bolan headshot

Bull Of The Day: Phreesia (PHR)

by Brian Bolan

This company has accelerated its push to profitability and that will bring in a whole new set of investors

Phreesia and LCI have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Phreesia and LCI have been highlighted as Zacks Bull and Bear of the Day.

New Strong Buy Stocks for January 29th

by Zacks Equity Research

PHR, SASR, QCRH, WDC and NU have been added to the Zacks Rank #1 (Strong Buy) List on January 29, 2023.

Best Momentum Stocks to Buy for January 11th

by Zacks Equity Research

ADMA, ARQT and PHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 11, 2024.

New Strong Buy Stocks for January 11th

by Zacks Equity Research

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

Does Phreesia (PHR) Have the Potential to Rally 30.09% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Phreesia (PHR) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 77.77% Upside in Phreesia (PHR): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Phreesia (PHR) points to a 77.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's What Key Metrics Tell Us About Phreesia (PHR) Q3 Earnings

by Zacks Equity Research

The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended October 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Compared to Estimates, Phreesia (PHR) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 9.33% and 1.22%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Phreesia (PHR) Rating Upgrade to Buy

by Zacks Equity Research

Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

How Much Upside is Left in Phreesia (PHR)? Wall Street Analysts Think 27.26%

by Zacks Equity Research

The consensus price target hints at a 27.3% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nextgen Healthcare (NXGN) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Nextgen Healthcare (NXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Should You Buy and Phreesia (PHR) Ahead of Earnings?

by Zacks Equity Research

Phreesia (PHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 22.22% and 12.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?